The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has presented a development strategy through 2030, aimed at modernising the healthcare regulatory system in light of contemporary scientific and technological advances. The primary goal of the initiative is to transform cutting-edge innovations into real improvements in patient health across all four nations of the United Kingdom. The strategy pays particular attention to adapting the regulatory framework to the rapid development of artificial intelligence in medicine, as well as to the growth of personalised treatment approaches that take into account individual patient characteristics. MHRA states its intention to build a more flexible, patient-oriented regulatory system capable of responding promptly to technological changes while maintaining high safety standards. The new approach is expected to accelerate the market entry of innovative medicines and medical technologies, while simultaneously ensuring proper quality and efficacy control. The Agency emphasises the importance of collaboration with the scientific community, technology developers and healthcare representatives to achieve the stated objectives. The initiative is viewed as a response to global challenges related to the digitalisation of medicine and the emergence of new classes of therapy, including gene and cell technologies. MHRA expects that the implementation of the strategy will strengthen the UK's position as a centre for medical innovation and increase patient confidence in the country's regulatory system.